The National Analytical Facility for Nutrition and Metabolism Research at the Tata Institute of Fundamental Research, Hyderabad (TIFRH), was inaugurated by the Chairman-Atomic Energy Commission (AEC) ...

People undergoing metabolic and bariatric surgery are less likely to develop psychiatric disorders than those treated with GLP-1 RAs.

Viking Therapeutics initiates VANQUISH phase 3 obesity clinical programme with GLP-1/GIP agonist VK2735: San Diego Thursday, June 26, 2025, 10:00 Hrs [IST] Viking Therapeutics, In ...

Study suggests emotional demands at work and in-person confrontations may increase diabetes risk by up to 24%.

Emotional demands at a workplace and in-person confrontations with colleagues can increase the risk of developing diabetes by ...

Altimmune, Inc.'s pemvidutide shows promising results in MASH resolution and weight loss, paving the way for phase 3 trials.

Altimmune shares cratered more than 50% on Thursday after its experimental obesity drug did not significantly improve liver ...

One of the most persistent misconceptions is that diabetes can spread through blood, a belief doctors are now strongly ...

Altimmune, Inc. (ALT) on Thursday said that its mid-stage study of Pemvidutide in metabolic dysfunction-associated ...

Packed with fibre, minerals, and antioxidants, they support everything from digestion to heart health and skin glow. Experts ...

India's anti-obesity drug market is currently valued at Rs 3,000-3,500 crore & is projected to grow nearly eightfold by 2030, ...

As per a recent report from ICMR, around 56% of the total disease burden in India is because of unhealthy dietary habits. A ...